• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Tuberculosis and Respiratory Diseases >Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
【2h】

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

机译：用伊马替尼成功治疗以前曾经历过甲磺酸伊马替尼诱导的肺炎的慢性粒细胞白血病患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.
机译：甲磺酸伊马替尼是一种靶向疗法，其作用是抑制bcr-abl融合癌蛋白的酪氨酸激酶，该蛋白对慢性粒细胞白血病（CML）具有特异性，而c跨膜受体对胃肠道间质瘤具有特异性。间质性肺炎是伊马替尼治疗的罕见不良事件。在临床上很难与传染性肺炎区分开，传染性肺炎由于潜在的疾病而经常发生。伊马替尼诱发的肺炎的标准治疗方法是中止药物治疗，并可选用皮质类固醇。但是，有几例伊马替尼成功重审的案例。我们描述了在3个月的随访后伊马替尼诱导的间质性肺炎和CML患者成功再挑战伊马替尼的病例，而基础疾病没有复发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号